Enzo Biochem, Inc. (ENZ) Financials
ENZ Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-01-31 | 99.1 million | 28.3 million |
| 2023-10-31 | 121.9 million | 43.4 million |
| 2023-07-31 | 121.9 million | 43.4 million |
| 2023-04-30 | 72.1 million | 53.1 million |
ENZ Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-01-31 | -9.0 million | 514000 |
| 2023-10-31 | -17.6 million | 868000 |
| 2023-07-31 | -17.6 million | 868000 |
| 2023-04-30 | -5.7 million | 939000 |
ENZ Net Income
No data available :(
ENZ Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-01-31 | 65.2 million | - | 3.6 million |
| 2023-10-31 | 82.4 million | - | 3.9 million |
| 2023-07-31 | 82.4 million | 269000 | 4.1 million |
| 2023-04-30 | 2.6 million | 247000 | 14.5 million |
ENZ Shares Outstanding
ENZ Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-01-31 | 25000 | 580000 | 5.1 million | - |
| 2023-10-31 | 573000 | 502000 | 23.3 million | - |
| 2023-07-31 | 254000 | 502000 | 27.2 million | - |
| 2023-04-30 | 666000 | 975000 | 4.3 million | 7.7 million |
ENZ Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-01-31 | 8.6 million | 4.3 million |
| 2023-10-31 | -19.7 million | 5.1 million |
| 2023-07-31 | 31.1 million | 19.5 million |
| 2023-04-30 | 16.1 million | 14.5 million |
ENZ
Price: $1.12
52 week price:
Earnings Per Share: -0.47 USD
P/E Ratio: -2.67
Exchange: NYQ
Sector: Healthcare
Industry: Diagnostics & Research
Volume: 12788
Ebitda: 111000Market Capitalization: 59.9 million